"Synergistic Improvements to Polynucleotide Vaccines" 09/828,505 Eyal Raz, et al.

1/7

#### FIG. 1

## Construct of Amb a1 cDNA - II

Full-length Amb a1 (396 codon)

Plant Leader Sequence (36AA)

Δ36 Amb a1

ssHAΔ36 Amb a1

Virus Leader Sequence (14AA)

2/7

FIG. 2

## Comparison of codon usage (Plant vs. Human)

HIS

	Plant	Human
CAT	83%	0%
CAC	17%	100%

GLN

	Plant	Human
CAA	90%	30%
CAG	10%	70%

**ASP** 

	Plant	Human		
GAT	76%	31%		
GAC	24%	69%		

GLU

	Plant	Human		
GAA	69%	25%		
GAG	31%	75%		

"Synergistic Improvements to Polynucleotide Vaccines" 09/828,505 Eyal Raz, et al.

3/7

#### FIG. 3

## Expression of Amb a1 in COS-7 cell - III

43 kDa	1 2	3	4	<b>5</b>	- 39	kDa
38 kDa <sup>┌</sup>						

1: Purified AgE

The graph along the first office and the first of the fir


2: Amb a1/pNDKm (x1)

3:  $\triangle$ 36Amb a1/pNDKm (x3)

4:  $ssHA\Delta 36Amb \ a1/pNDKm$  ( x 3 )

5:  $hssHA\Delta 36Amb$  a1/pNDKm ( x 10 )

#### Induction of Antigen-specific Antibody and Cytokine *in vivo* - III




Con the time that will the time that

The first that the fifth the first in

5/7

### Induction of Antigen-specific Antibody and Cytokine *in vivo* - VI


(Co-injection of ISS-ODN with 50µg of hssHA $\Delta$ 36Amb a1/pNDKm)



6/7

FIG. 6

In vivo Efficacy of ISS-ODN (dsPO vs. ssPS)



## 1: PBS, 2: ISS-ODN, 3: M-ODN

- Injection of ISS-ODN(i.v.) [200µg/mouse]
- Isolation of spleen after 2 hr post-injection
- Isolation of mRNA
- Detection of IL-6/IL-12 transcript by RT-PCR

0.5 mg/mouse

50µg/mouse 50µg/mouse

10µg/mouse

# Reduction of Amb a1-specific IgE in vivo (week 8)

FIG. 7A

